Invasive Fungal Infections
Conditions
Keywords
Micafungin, Candida, Aspergillosis, Antifungal
Brief summary
The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.
Interventions
DRUGMicafungin
Intravenous
Sponsors
Astellas Pharma China, Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy * Patients received Micafungin treatment at least 1 dose
Exclusion criteria
* Patients received Micafungin treatment combined with other antifungal drugs at the same time * Neither efficacy or safety can be evaluated because of missing data, confused record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall success rate | Up to 12 months | Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100% |
Secondary
| Measure | Time frame |
|---|---|
| Overall incidence and severity of adverse events | Up to 12 months |
| Overall incidence and severity of adverse drug reactions | Up to 12 months |
Countries
China
Outcome results
None listed